(Q37582338)

21 August 2017

1 reference

title

Bayesian statistics in oncology: a guide for the clinical investigator (English)

1 reference

21 August 2017

0 references

George Tomlinson

2

0 references

Michel Adamina

series ordinal

1

object named as

Michel Adamina

1 reference

21 August 2017

3

Ulrich Guller

1 reference

PubMed ID

19691089

21 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

21 August 2017

1 reference

21 August 2017

115

1 reference

21 August 2017

23

1 reference

21 August 2017

5371-5381

1 reference

Toward evidence-based medical statistics. 1: The P value fallacy

21 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

Stopping at nothing? Some dilemmas of data monitoring in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

Effect of screening and adjuvant therapy on mortality from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

When did Bayesian inference become "Bayesian"?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Human genome ultraconserved elements are ultraselected

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

A Bayesian approach to stochastic cost-effectiveness analysis. An illustration and application to blood pressure control in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Decision theory: what "should" the nervous system do?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Evidence-based medicine as Bayesian decision-making

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Prioritizing climate change adaptation needs for food security in 2030.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Monitoring of large randomised clinical trials: a new approach with Bayesian methods

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Introduction to Bayesian methods II: fundamental concepts.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Combination of direct and indirect evidence in mixed treatment comparisons

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Quantifying and documenting prior beliefs in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

The CHART trials: Bayesian design and monitoring in practice. CHART Steering Committee.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Prime time for Bayes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Interpreting statistics in medical literature: a vade mecum for surgeons

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Introduction to Bayesian methods I: measuring the strength of evidence.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Early stopping in clinical trials and epidemiologic studies for "futility": conditional power versus sequential analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

A parallel phase I/II clinical trial design for combination therapies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Seamlessly expanding a randomized phase II trial to phase III.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Meta-analyses and adaptive group sequential designs in the clinical development process

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Conditional bias of point estimates following a group sequential test.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Bayesian perspectives for epidemiological research: I. Foundations and basic methods

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Recent developments in meta-analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Bayesians in clinical trials: asleep at the switch.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Bayeswatch: an overview of Bayesian statistics.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24628

7 January 2021

Identifiers

DOI

10.1002/CNCR.24628

1 reference

21 August 2017

1 reference

PubMed ID

19691089